Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Abiraterone Acetate-5,6-Epoxide

● Under Development

Catalogue No.:	VL830024
CAS No.:	N/A
Mol. Formula:	C26H33NO3
Mol. Weight:	407.55 g/mol

How can we help?

Add to RFQ list

Additional information on Abiraterone Acetate-5 | 6-Epoxide

Parent drug

Abiraterone

IUPAC Name

(3S, 6aS, 6bS, 9aS, 11aS, 11bR)-9a, 11b-dimethyl-9-(pyridin-3-yl)-1, 2, 3, 4, 5a, 6, 6a, 6b, 7, 9a, 10, 11, 11a, 11b-tetradecahydrocyclopenta[1, 2]phenanthro[8a, 9-b]oxiren-3-yl acetate

Pharmacopoeial Synonyms

N/A

Other Synonyms

N/A

Smiles

CC(O[C@H](C1)CC[C@]2(C)[C@@]3([H])CC[C@@](C(C4=CC=CN=C4)=CC5)(C)[C@]5([H])[C@]3([H])CC6C21O6)=O

InChI

InChI=1S/C26H33NO3/c1-16(28)29-18-8-11-25(3)22-9-10-24(2)20(17-5-4-12-27-15-17)6-7-21(24)19(22)13-23-26(25,14-18)30-23/h4-6,12,15,18-19,21-23H,7-11,13-14H2,1-3H3/t18-,19-,21-,22-,23?,24+,25+,26?/m0/s1

Description

The compound Abiraterone Acetate-5,6-Epoxide is a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Abiraterone. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. Abiraterone Acetate-5,6-Epoxide or (3S,6aS,6bS,9aS,11aS,11bR)-9a,11b-dimethyl-9-(pyridin-3-yl)-1,2,3,4,5a,6,6a,6b,7,9a,10,11,11a,11b-tetradecahydrocyclopenta[1,2]phenanthro[8a,9-b]oxiren-3-yl acetate, that inhibits 17a-hydroxylase CYP17 and is used in the treatment of prostate cancer.

References

Goldberg, Tamara, and Evangelina Berrios-Colon. â€œAbiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer.â€ Pharmacy and Therapeutics, vol. 38, no. 1, 1 Jan. 2013, pp. 23â€“26, www.ncbi.nlm.nih.gov/pmc/articles/PMC3628169/.